Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Urodynamic Studies: Uroflowmetry01:19

Urodynamic Studies: Uroflowmetry

2.6K
Uroflowmetry is a non-invasive urodynamic test designed to measure various aspects of urination, including volume, flow rate, and the time to void. This test is crucial for diagnosing and assessing conditions such as bladder outlet obstruction, bladder dysfunction, incomplete bladder emptying, incontinence, and urinary tract blockages caused by benign prostatic hyperplasia (BPH) and urethral strictures.Pre-Test Instructions:Before a uroflowmetry test, patients are typically advised to drink...
2.6K
Male Sexual Response: Erection & Ejaculation01:17

Male Sexual Response: Erection & Ejaculation

15.8K
Sexual stimulation can take various forms, such as physical touch and visual or auditory cues. When this happens, the parasympathetic reflex in the sacral portion of the spinal cord is activated. This reflex stimulates the release of nitric oxide (NO), which then dilates the arterioles in the penis, increasing blood flow to the erectile tissues - the corpora cavernosa and corpus spongiosum.
The blood filling the erectile tissues compresses the veins, which helps to prevent blood from leaving...
15.8K
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

201
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
201
Disorders of the Male Reproductive System01:20

Disorders of the Male Reproductive System

3.9K
Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
3.9K
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers01:22

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

1.3K
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
1.3K
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

465
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
465

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ten Year Update on the Online and Social Media Presence of Australian and New Zealand Urologists.

ANZ journal of surgery·2026
Same author

Periprostatic Nerve Block During Transperineal Prostate Biopsy Under General Anaesthesia: Protocol for a Multicentre Pilot Randomised Controlled Trial.

Cancers·2026
Same author

The state of urology education in Australia and New Zealand: a regional survey.

BJU international·2026
Same author

A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.

Cancer research communications·2026
Same author

Trust, but Verify: An Exploratory Audit of Predatory Journal and Publisher Solicitations.

ANZ journal of surgery·2026
Same author

High-dose vitamin D supplementation and prostate cancer progression: a phase II randomised trial in localised prostate cancer cases with intermediate risk of progression (ProsD).

British journal of cancer·2025

Related Experiment Video

Updated: Dec 29, 2025

Author Spotlight: Advanced Treatment of Seminal Duct Blockage Employing Endoscopy-Mediated Semen Channel Refluviation
03:51

Author Spotlight: Advanced Treatment of Seminal Duct Blockage Employing Endoscopy-Mediated Semen Channel Refluviation

Published on: December 8, 2023

4.2K

Alfuzosin and Its Effect on Ejaculatory Dysfunction: A Systematic Review.

Haywood E L Yeung1, Stephen J Sena1, Ross J Calopedos1

  • 1Department of Urology, Sydney Adventist Hospital Clinical School, University of Sydney, Wahroonga, NSW, Australia.

The World Journal of Men'S Health
|February 4, 2020
PubMed
Summary

Alfuzosin may improve ejaculatory function and lower urinary tract symptoms (LUTS). This medication should be considered for sexually active men experiencing deteriorating ejaculation alongside LUTS.

Keywords:
AlfuzosinBenign prostatic hyperplasiaEjaculationLower urinary tract symptomsSexual dysfunction, Physiological

More Related Videos

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility
04:22

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility

Published on: May 30, 2025

703
Ultrasonography of the Adult Male Urinary Tract for Urinary Functional Testing
05:25

Ultrasonography of the Adult Male Urinary Tract for Urinary Functional Testing

Published on: August 14, 2019

19.8K

Related Experiment Videos

Last Updated: Dec 29, 2025

Author Spotlight: Advanced Treatment of Seminal Duct Blockage Employing Endoscopy-Mediated Semen Channel Refluviation
03:51

Author Spotlight: Advanced Treatment of Seminal Duct Blockage Employing Endoscopy-Mediated Semen Channel Refluviation

Published on: December 8, 2023

4.2K
Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility
04:22

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility

Published on: May 30, 2025

703
Ultrasonography of the Adult Male Urinary Tract for Urinary Functional Testing
05:25

Ultrasonography of the Adult Male Urinary Tract for Urinary Functional Testing

Published on: August 14, 2019

19.8K

Area of Science:

  • Urology
  • Pharmacology
  • Sexual Medicine

Background:

  • Lower urinary tract symptoms (LUTS) are common in men with benign prostatic hyperplasia (BPH).
  • Ejaculatory dysfunction (EjD) is a potential side effect of BPH treatments.
  • Alfuzosin is a medication used to treat LUTS associated with BPH.

Purpose of the Study:

  • To evaluate the impact of alfuzosin on ejaculatory function.
  • To assess alfuzosin's effect on LUTS using the International Prostate Symptom Score (IPSS).
  • To measure changes in ejaculatory function with the Male Sexual Health Questionnaire (MSHQ)-EjD Short Form.

Main Methods:

  • Systematic literature search of MEDLINE, PubMed, Scopus, Embase, and grey literature up to January 2017.
  • Included six cohort studies (2008-2015) with 1,371 male patients (median age 62.3 years).
  • Analyzed data on IPSS for LUTS and MSHQ-EjD Short Form for ejaculatory function.

Main Results:

  • Alfuzosin treatment showed a median decrease of 6.6 in IPSS scores, indicating LUTS improvement.
  • A median increase of 1.9 in MSHQ-EjD scores was observed, suggesting improvement in ejaculatory function.
  • The review confirmed an association between LUTS and sexual function.

Conclusions:

  • Alfuzosin may improve ejaculatory function in addition to LUTS.
  • Consider alfuzosin for sexually active men with LUTS and concerns about ejaculation.
  • Further research may explore the mechanisms behind alfuzosin's positive impact on ejaculatory function.